A Phase 2, Open-Label, Multicenter, Dose-Escalation and Expansion Study of Venetoclax in combination with Pomalidomide and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2018
This article has no abstract
Epistemonikos ID: 08af66e619487b72d65ef069c6c3639ff7495b82
First added on: Jan 23, 2025